Becton Dickinson and Company (NYSE:BDX) : Traders are bullish on Becton Dickinson and Company (NYSE:BDX) as it has outperformed the S&P 500 by a wide margin of 2.1% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.23%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.54% in the last 1 week, and is up 3.75% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 20.34% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $176.24 and the one year low was seen on Sep 28, 2015. The 50-Day Moving Average price is $168.44 and the 200 Day Moving Average price is recorded at $155.54.
The stock has recorded a 20-day Moving Average of 4.1% and the 50-Day Moving Average is 5.45%.
Becton Dickinson and Company (NYSE:BDX): stock turned positive on Friday. Though the stock opened at $174.08, the bulls momentum made the stock top out at $176.24 level for the day. The stock recorded a low of $172.9 and closed the trading day at $175.64, in the green by 1.43%. The total traded volume for the day was 891,802. The stock had closed at $173.17 in the previous days trading.
In an insider trading activity, Gallagher John E, officer (VP, Corp Finance and Treasurer) of Becton Dickinson & Co, unloaded 1,931 shares at an average price of $169.87 on June 13, 2016. The total amount of the transaction was worth $328,019, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.